Valuation: Grifols, S.A.

Capitalization 5.72B 6.73B 5.24B 4.95B 9.18B 635B 9.29B 62.09B 24.19B 305B 25.26B 24.73B 1,054B P/E ratio 2026 *
12.2x
P/E ratio 2027 * 8.75x
Enterprise value 14.22B 16.74B 13.02B 12.3B 22.83B 1,578B 23.1B 154B 60.15B 758B 62.8B 61.49B 2,619B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 1.67x
Free-Float
79.23%
Yield 2026 *
2.09%
Yield 2027 * 2.86%
1 day-2.52%
1 week-2.04%
Current month-0.45%
1 month-5.51%
3 months-19.35%
6 months-16.83%
Current year-16.64%
1 week 8.72
Extreme 8.716
9.24
1 month 8.68
Extreme 8.682
9.66
Current year 8.43
Extreme 8.432
11.7
1 year 8.01
Extreme 8.01
13.7
3 years 6.36
Extreme 6.362
15.92
5 years 6.36
Extreme 6.362
25.94
10 years 6.36
Extreme 6.362
34.31
Manager TitleAgeSince
Chief Executive Officer 57 01/04/2024
Director of Finance/CFO 49 16/09/2024
Compliance Officer 54 01/01/2014
Director TitleAgeSince
Chairman 76 25/01/2010
Director/Board Member 70 13/04/2000
Director/Board Member 62 24/05/2015
Change 5d. change 1-year change 3-years change Capi.($)
-2.69%-2.04%+9.34%-6.38% 6.73B
+1.00%+1.43%+29.90%-5.41% 72.14B
+0.82%+2.63%+54.63%+180.37% 52.16B
-0.81%+46.80%+46.80%+46.80% 46.76B
-1.74%-3.97%-50.03%-60.21% 42.91B
+1.81%+3.60%+63.70%-38.35% 28.25B
-1.21%-2.65%+74.08%+118.98% 20.19B
+0.84%+1.31%+64.37%+49.23% 19.53B
+13.67%+19.31%+122.03%-58.91% 19.26B
-1.85%+0.79%+46.14%+67.51% 16.66B
Average +0.99%+1.05%+46.10%+29.36% 32.46B
Weighted average by Cap. +0.75%+0.41%+39.38%+33.42%

Financials

2026 *2027 *
Net sales 7.71B 9.08B 7.06B 6.67B 12.38B 855B 12.52B 83.69B 32.61B 411B 34.05B 33.34B 1,420B 8.23B 9.68B 7.53B 7.11B 13.21B 913B 13.36B 89.28B 34.78B 438B 36.32B 35.56B 1,515B
Net income 517M 608M 473M 447M 829M 57.31B 839M 5.61B 2.18B 27.51B 2.28B 2.23B 95.13B 710M 836M 650M 614M 1.14B 78.76B 1.15B 7.71B 3B 37.81B 3.13B 3.07B 131B
Net Debt 8.5B 10.01B 7.79B 7.35B 13.65B 943B 13.81B 92.28B 35.95B 453B 37.54B 36.76B 1,566B 7.99B 9.41B 7.32B 6.91B 12.83B 887B 12.98B 86.77B 33.81B 426B 35.3B 34.57B 1,472B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (2.9%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
Employees
25,258
Date Price Change Volume
08/05/26 8.924 -2.53% 4,196,674
07/05/26 9.156 +0.90% 1,198,009
06/05/26 9.074 +0.67% 1,830,309
05/05/26 9.014 -1.01% 1,433,865
04/05/26 9.106 +1.63% 1,718,300
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
9.156EUR
Average target price
14.73EUR
Spread / Average Target
+60.87%

Quarterly revenue - Rate of surprise